United Therapeutics Corporation

NASDAQ:UTHR

Biotechnology

Healthcare
$577.34 -3.27%

-$18.01 today

Market cap
$24.59B
Beta
0.57
P/E (TTM)
18.0
EPS (TTM)
$29.60
52W Low $272.12High $609.35

Volume 0.42M

Average 0.52M

UTHR EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

United Therapeutics CorporationNASDAQ: UTHR

EPS (Basic) · Q2 FY2026 · quarter ended Jun 2026

EPS (Basic) growth accelerates

Q2 FY2026 EPS (Basic) of $7.82 rose 14.0% year over year, ahead of the +9.1% change in trailing-twelve-month EPS (Basic). Sequentially, it rose 23.7% from the prior quarter. Over 3 fiscal years it compounded at +23.5% a year.

Context

  • EPS (Basic) increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 10 analysts of $24.65 (-18.2%) for the fiscal year ending Dec 2026, a slowdown from the +14.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
$7.82+23.7% QoQ
Last fiscal yearDec 2025
$30.13+14.0% YoY
LTMJun 2026
$30.23+9.1% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.0%-22.3%-36.3 pp
1 year+14.0%-18.2%-32.1 pp
3-year CAGR+23.5%+4.5%-19.0 pp
5-year CAGR+11.2%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
30.13 USD
Year-over-year change
+14.0%
4-year CAGR
+29.8%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How UTHR compares with its peers on the latest reported figures

  • UTHR's LTM Jun 2026 EPS (Basic) of $30.23 is the highest of the 5 companies compared; the peer median is -$1.05.
  • Its year-over-year change of +9.1% is the 4th highest of 5, against a peer median of +47.4%.
UTHR Competitors Peer median
EPS (Basic) for UTHR and competitors
Company Period LTM YoY 3-year CAGR
UTHRUnited Therapeutics CorporationLTM Jun 2026$30.23 +9.1%+23.5%
LQDALiquidia CorporationLTM Jun 2026$1.57 +192.8%—
IKTInhibikase Therapeutics, Inc.LTM Mar 2026-$0.54 +66.9%—
TVTXTravere Therapeutics, Inc.LTM Sep 2026-$1.56 -48.6%—
INSMInsmed IncorporatedLTM Jun 2026-$4.11 +28.0%—
Peer median (excluding UTHR) -$1.05+47.4%—

Competitors are the stored peer set for UTHR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue1.69B1.94B2.33B2.88B3.18B
Cost of Revenue122.5M146.7M257.5M309.7M384.4M
Gross Profit1.56B1.79B2.07B2.57B2.8B
Gross Margin92.7%92.4%88.9%89.2%87.9%
Research & Development540.1M322.9M408M481M550M
Selling, General & Admin467M487M477.1M638.6M731.1M
Operating Expenses1.01B809.9M885.1M1.19B1.28B
Depreciation & Amortization49.9M51.3M53.2M72.5M85.6M
EBITDA736.8M1.04B1.39B1.65B1.82B
EBITDA Margin43.7%53.7%59.6%57.5%57.2%
Operating Income555.9M979.7M1.18B1.38B1.52B
Operating Margin33.0%50.6%50.9%47.9%47.7%
Interest Income16.7M45.2M162.7M199.1M192M
Interest Expense18.6M32.4M59.3M42.9M19.5M
Other Income / Expenses38M(29.1M)89.4M162M196.7M
Income Before Tax593.9M950.6M1.27B1.54B1.71B
Pre-Tax Margin35.2%49.1%54.7%53.5%53.9%
Income Tax Expense118.1M223.3M289.5M343.9M379.2M
Net Income475.8M727.3M984.8M1.2B1.33B
Net Margin28.2%37.6%42.3%41.5%41.9%
EPS (Basic)10.6015.9821.0426.4430.13
EPS (Diluted)10.0615.0019.8124.6427.86
Weighted Avg Shares44.9M45.5M46.8M45.2M44.3M
Weighted Avg Shares (Diluted)47.3M48.5M49.7M48.5M47.9M

United Therapeutics Corporation

NASDAQ:UTHR

Intrinsic Alpha fair value

Locked

Current Price

$577.34

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.